Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention
Paper is First in a Series Based on Presentations from Cervical Cancer
Prevention Forum Hosted by SGO
CHICAGO, Aug. 3 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) has published the first in a series of four papers on a variety of cervical cancer
Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk
FRANKLIN LAKES, N.J., July 30 /PRNewswire-FirstCall/ -- A new analysis finds that women in New Jersey who take the breast cancer
drug tamoxifen in conjunction with certain popular antidepressants may be at a higher risk for a breast cancer
In May, Medco Health Solutions, ...
Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy
NEWPORT BEACH, Calif., July 28 /PRNewswire/ -- Hoag Memorial Hospital Presbyterian today announced promising data from a clinical study showing patient-specific cancer
vaccines derived from patients' own cancer
cells and immune cells were well tolerated and resulted in impressive lo...
First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center
WISCONSIN RAPIDS, Wis., July 23 /PRNewswire/ -- Earlier this month the University of Wisconsin Cancer
Center Riverview became the first medical facility in the world to treat patients with a breakthrough treatment of skin cancer. Located within Riverview Hospital, Wisconsin Rapids, ...
National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness
SEATTLE, July 21 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today that researchers from the Laboratory of Molecular Pharmacology at the National Cancer
Institute presented new preclinical research identifying unique anti-tumor mechanisms of br...
UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201
US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer
Phase II of the trial was presented in 2009 ASCO Plenary Session
US Oncology, Inc . today announced that US Oncology Research will participate...
Northern California Cancer Center's First-of-Its-Kind Research Reveals Low Socioeconomic Status Often Equals Poor Chance of Lymphoma Survival
C onsiderably higher risk of follicular lymphoma-related death in poorer neighborhoods may be linked to care required to address waxing and waning progression of disease
FREMONT, Calif., July 20 /PRNewswire-USNewswire/ -- The Northern California Cancer
International Journal of Occupational and Environmental Health Features Discovery of Asbestos-Related Pain Origin from Scientists at the Karmanos Cancer Institute in Detroit
DETROIT, July 20 /PRNewswire-USNewswire/ -- Scientists at the Barbara Ann Karmanos Cancer
Institute's National Center for Vermiculite and Asbestos-Related Cancers (NCVAC) have discovered a probable reason for the unrelenting chest pain experienced in certain patients with asbestos-r...
Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program
FREMONT, Calif., July 16 /PRNewswire/ -- Velos, Inc., the trusted leader in clinical research management systems, announced today the availability of new system capabilities to ensure that the cancer
center community can fulfill new registration requirements for the U.S. National Cancer
Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
NEW YORK, July 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today the initiation of a Phase 1 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for recurrent solid tumors in pediatric patients. This Phase 1 study is now ope...
CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
VIENNA, Va., July 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ), a late stage cancer
immunotherapy company, announced today that Dr. Eyal Talor, CEL-SCI's Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI's Clinical Cent...
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
THOUSAND OAKS, Calif., July 7 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,049 patients with advanced breast cancer
met its primary and ...
USC Keck School of Medicine's Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic
LOS ANGELES, July 7 /PRNewswire-USNewswire/ -- The University of Southern California today announced that Dr. Alan Epstein of the USC Keck School of Medicine has received approval for a $3.5 million drug development project through the Rapid Access to Intervention Development (RAID) program of...
Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet
LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical cancer
vaccine is published today in The Lancet . The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix (R) is highly effective at protecting against the two most common cervical cance...
Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
HUNTINGTON BEACH, California and AMSTERDAM, June 23 /PRNewswire/ --
Agendia, a world leader in molecular cancer
diagnostics, today announced the
inclusion of its breast cancer
recurrence test MammaPrint in St. Gallen's
2009 International Expert Consensus on the primary therapy of early breast
Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
Therapy targets folate receptors found on cancer
cells otherwise resistant to standard chemo
ZION, Ill., June 17 /PRNewswire-USNewswire/ -- Cancer
Treatment Centers of America (CTCA) at Midwestern Regional Medical Center, a leading provider of innovative cancer
care for patients living wi...
Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
CHICAGO, June 15 /PRNewswire-USNewswire/ -- Vitamin D deficiency was found to be prevalent in cancer
patients regardless of nutritional status, according to the results of a recent study conducted at Cancer
Treatment Centers of America (CTCA). Based on these results, CTCA researchers determine...
Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients
CHICAGO, June 15 /PRNewswire-USNewswire/ -- Body mass index (BMI) should be taken into account when assessing a cancer
patient's vitamin D status, according to researchers at Cancer
Treatment Centers of America (CTCA), who found that obese cancer
patients had significantly lower levels of vita...
Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
SAN FRANCISCO, June 11 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada), a clinical-stage biopharmaceutical company, announced today that a $10 million grant from the Ontario Institute for Cancer
Research (OICR) has been received by the Centre for Cancer
Therapeutics at Ottawa...
Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis
MORGANTOWN, W.Va., June 5 /PRNewswire-USNewswire/ -- It's common knowledge that smoking raises risks of lung cancer. And yet researchers haven't known whether continued smoking by lung cancer
patients would increase the risk of the cancer's spread.
Researchers at West Virginia Univers...
Advance in Bowel Cancer Test Research
SYDNEY, June 3 /PRNewswire/ -- Australian researchers have developed gene expression biomarkers which can accurately discriminate pre-cancerous and cancerous colorectal growths from non-cancerous controls.
Being presented today at the Digestive Disease Week conference in Chicago, the prelimin...
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
PARIS and BRISBANE, California, June 3 /PRNewswire-FirstCall/ --
- Data Highlighted in Plenary Session of 2009 American Society of
Clinical Oncology Annual Meeting
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) and its fully owned
subsidiary, BiPar Sciences, today announced resu...
Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer
- 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer
- 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cance...
Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
-- Findings Presented at American Society of Clinical Oncology 2009 Annual Meeting and Included in Best of ASCO(R) Educational Program --
SAN FRANCISCO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced the presentation of new clinical results from a Phase 1-...
Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
Abstract # 6053
ORLANDO, Fla., June 1 /PRNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer
Institute in Detroit presented data demonstrating the feasibility of long-term, low-dose adjuvant chemotherapy, which resulted in fewer tumor recurrences and cancer
metastases in patients wit...
Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
Recently Expanded Clinical Program Now Includes Solid and Hematological Malignancies
ROCKVILLE, Md., June 1 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer
today announced the presentation ...
Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
ORLANDO, Fla., May 31 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today that Phase III trial data showed the addition of Lilly's GEMZAR(R) (gemcitabine HCl for injection) to the current standard of care provided a statistically significant increase in progression-free survival at thr...
New Research Shows Antidepressants May Thwart Breast Cancer Treatment
Popular antidepressants taken with tamoxifen can increase the risk of breast cancer
PHILADELPHIA, May 30 /PRNewswire-USNewswire/ -- A new study found that taking tamoxifen with certain antidepressants more than doubled the risk of breast cancer
recurrence in women taking both ...
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
ORLANDO, Fla., May 30 Data from the Phase III ZODIAC study in advanced non-small cell lung cancer
patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, d...
Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy
Abstract # 25670
ORLANDO, Fla., May 29 /PRNewswire-USNewswire/ -- The American Society of Clinical Oncology (ASCO) has selected new breast cancer
research conducted at the Barbara Ann Karmanos Cancer
Institute in Detroit for posting on ASCO's Web site. Karmanos' potentially ground-breaking fi...
Cardiovascular Fitness Not Affected by Cancer Treatment
GUMC Researchers Identify Simple Test To Help Survivors Start Exercise Routine Based on Current Cardiovascular Fitness Level
WASHINGTON, May 28 /PRNewswire-USNewswire/ -- The cardiovascular fitness level of cancer
survivors is not affected by many standard cancer
therapies, say researchers fr...
BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
TURKU, Finland, May 28 /PRNewswire/ -- BioCis Pharma Ltd., a
privately-held drug development company with its headquarters in Turku,
Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical
instillation solution, a novel anti-cancer drug for urinary bladder cancer.
CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
ATLANTA, May 27 /PRNewswire-USNewswire/ -- The Centers for Disease Control and Prevention (CDC) Foundation, CDC and Amgen today announced the launch of a three-year campaign to reduce infections among cancer
patients. The campaign will provide resources and educational tools to help patients, fami...
Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development
Data show superiority of endoscopic ablation therapy using the HALO System for eradicating Barrett's esophagus in randomized, multicenter, sham controlled trial
SUNNYVALE, Calif., May 27 /PRNewswire/ -- Results from a clinical study published today in the New England Journal of Medicine rev...
Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
Five Multi-Disciplinary SU2C "Dream Teams" Selected With More Than 200 Researchers from 20 Leading Institutions
Initiative's Pioneering Objective is to Expedite New Treatments from Lab to Patient with Potential for Results that Impact Many Forms of Cancer
Unique Translational Model...
Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
OXFORD, England, May 18 /PRNewswire/ --
- New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of
Oxford BioTherapeutics (OBT) today announced a strategic alliance with
GlaxoSmithKline to discover, develop and commercialise novel, therapeutic
Creighton Medical Laboratories First to Offer New Cancer Test
OMAHA, Neb., May 15 /PRNewswire/ -- Creighton Medical Laboratories, based at Creighton University School of Medicine in Omaha, announced today that it has become the first clinical laboratory worldwide to offer a new and more effective testing method for cancer.
The method, called SNP arra...
BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer
and infectious disease, announced today that the results from a Phase I/II combination study in previously untreated patients with head and neck cancer
Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
Technology to improve accuracy of ovarian cancer
TAMPA, Fla., May 14 /PRNewswire/ -- Moffitt Cancer
Center and Frantz BioMarkers, LLC have signed a license agreement on phospholipid biomarkers of ovarian cancer. Frantz BioMarkers, which has been granted exclusive worldwide ...
Hooters of Orange Park to Host Charity Car Wash Raising Money for Breast Cancer Research
ATLANTA, May 8 /PRNewswire/ -- On May 9th, the Hooters of Orange Park is hosting a car wash to raise money for breast cancer
research. The car wash begins at 10 AM at the Hooters of Orange Park located at 1740 Wells Road. The restaurant can be reached at (904) 215-5858.
All donations from t...